Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Been away from this board for quite a while since I reached my limit with the calamitous drops in the share price. Now it seems there is some new interest trying to get the price out of the gutter. I know there are two trials, Mitigate and Brave, driving some new interest. Can anyone bring me up to date on expected public read out dates for these? I see a lot of references to these two but no dates so far.
Could this not also be protection against a perceived hostile threat of take over?
Regarding CVS, I just checked prescription drug cost for my silverscript part D plan. Vascepa copay is $482 plus for three months, and generic V is not covered. (Silverscript is a CVS/caremark brand)
If you think you are not at serious risk then it’s not your own protection you should be thinking about, but rather give a thought to all the people who are more vulnerable to the disease with whom you might come in contact as a carrier.
That won’t even support the E&O money-grab program.
If Amarin does not pursue further legal paths and win, then the US market is lost completely, except for possibly some small salvage for them to sell a generic V in competition with 20 other generic producers. The US market has been successfully stolen. The insurance companies will demand that all V prescriptions are filled from the lowest-priced equivalent. The R-it indication is lost to the generics.
This is my last post here since I bailed out this morning. I will not look back. I don’t have any interest in holding dead money any longer.
rt.com! Really? Russia Today is Russian state controlled media, and can be counted on to tell anything but the truth.
I am immune suppressed following a liver transplant 20 years ago. Immune suppression raises my susceptibility to skin cancers about 30-fold over gen pop. I have to see a dermatologist a few times a year to have any suspected skin lesions freeze dried or surgically removed. For several years now I’ve been following the dermatologist’s recommendation of supplementing with D3. I take 50,000 units weekly. My heart health and lipid profile are good to very good, aside from some PVCs and PACs, so it’s unlikely that I can get a script for V on label or off.
To refer to Judge Du as a liberal is, in my opinion, an insult to liberals. She is a flat-out commie. She does not respect property rights and has no problem seizing private property for redistribution to communes.
The first comment on that trade indicated that it was at the bid. If that’s the case then it’s a bullish play for income or a willingness to buy at $6 if shares are put to the trader. If there are other legs to the trade then the analysis is more complex than we can know. Huh
If DU’s irresponsible decision is allowed to stand there will be no end of assaults on the Marine carve-out indication and the cost of settlements will be infinite. In addition, pharmaceutical innovation will slow to a trickle. The only scenario that works is for the CAFC to make the obvious decision and void DU’s ruling (without remand if that is possible).
I can’t help but think that her action came not from stupidity but from deliberate political intent. Catastrophic damage to a company and its shareholders in pursuit of her agenda meant nothing to her. I believe sanctions are in order.
Agree. This was not just an activist decision in my opinion. It was a corrupt one.
Amarin will continue to sell its product. What the judge did in her infinitesimal wisdom was to declare poaching legal for other comers.
No one on this board, except the judge herself and her clerk if they were, foolishly, posting on this board, has the faintest clue when the judgment will be rendered, except for the fact that the judge gave the target date of the end of March.
I think the market agrees with your opinion, marjak. If it did not agree there would have been a massive downtick.
And now, on a lighter note, saw this on Stocktwits today:
https://stocktwits.com/buckfama/message/201524971
I haven’t seen any post from dmiller saying he sold. He did say he stopped buying but was holding 250k shares. I’m not dm and did bail out of my considerably smaller position, which I will probably rue.
I’m pretty sure that if a person or entity owns 10% or more of an equity he/it becomes an insider and subject to insider reporting rules.
The stations raise their prices immediately in response to oil price changes because they use a method called replacement cost. In this method the price at the pump should usually reflect the cost to replace it and a normal markup. The is not gouging. The fuel in the underground tanks is a capital investment that remains constant.
Yes, retail. I realize the market maker/s will be close to delta neutral as a rule.
Things to note about Max Pain:
1. It doesn’t matter how many contracts are open at a particular strike. What matters is the value of all the open contracts which will expire in the money at a particular level.
2. The picture is totally complicated by the fact that an open contract can be long or short, so for all we know there could be net zero value of the open contracts at any strike, if there were an equal number of long and short contracts open.
Max Pain is that price level at which option buyers suffer the maximum pain (greatest loss) and option sellers suffer the least pain (least loss). In the case of the January 17 expiration the curve is fairly shallow between $15 and $19, so it’s possible we don’t go much lower than where we are now. Regardless of where it closes within that range there will be a lot of money changing hands next weekend. With the current open interest the value of all the expiring in-the-money options will be between $30 and $34 million if the price at expiration is within that band.
I forgot about your qualifying experience as CEO of $7 billion biotech company.
I take it you yourself are not on Medicare with a part D plan, or at least you never experience the donut hole personally. My circumstances are such that I nearly always pass through it to the other side. Since Bush2 there have been subsidies to help seniors pay their drug costs when they’re in the donut hole, so while my donut hole co-pay for a particular drug might be $400, I might receive a subsidy of $250 toward that cost making my effective co-pay $150. Frequently my copay inside the donut hole is lower than before I enter it.
More like Apple and Joe’s Bait and Oil.
If the defendants were to prevail on the issue of obviousness then the patent is invalidated and inducement becomes irrelevant. It is highly probable but not 100% certain that Amarin wins the obviousness question, and in that event there is no doubt that they will win on inducement.
Sorry but placing a sell order will not remove your shares from the borrow pool if the shares are in a margin account. What you have stated is just a persistent myth
AF has no medical/scientific/mathematical education whatsoever. He was a political science major. To say he has little to no understanding of the subject matter about which he writes is an understatement.
Agreed. Adjunctive to a primary cardiac therapy.
Just to be clear, adjunctive (secondary) refers to adding it to patients already taking a statin. Both primary and secondary prevention are on the label, with primary being limited to diabetics plus 2 risk factors.
Please accept a minor correction: a kilo of gold or other precious metal, 1000 grams, converts to 35.27 Troy ounces, where each Troy ounce is approximately 31.1 grams.
MTNB and ACST are all hype no cattle. What goes up will come down imo. A lot of dreamers think they will coattail on AMRN’s rocketship. Big disappointment looming for them.
Even if they show greater bio availability they will need an outcomes trial to claim CVD risk improvement. That’s a whole lot of money and a whole lot of years away from competing with Vascepa. There is no coattail effect available for them. You want the label you run the outcomes trial on a large scale for a lot of years.
I strongly suspect there was considerable short covering on Friday, November 15 which is not reflected in the current short interest report, for which the effective date was November 13. November 15th was the settlement date for trades of November 13th.
That Friday is not included in this SI report. The cut off for the effective date was Wednesday. Friday was just the settlement date for Wednesday’s trades.
You are a newbie and JL is one of the most established veterans on the board. He knows more about the science than most posters here and he’s been invested since the beginning. It was his posts about the science that kept many people on the board invested through the hard times and why those same investors are now rich. I didn’t see his post today as a brag or boast or anything like that so maybe you just got up on the wrong side of the bed.
That’s the sound you make to express seeing or hearing something gross.
There are literally dozens of posts on this board telling you why Acasti is a bad bet. If you do a little homework and read some of those messages you will have your answer.
Matinas is a wanabee and nothing more. As I recall, and I’m not interested in looking it up again, they ran a very short term very small ‘n’ phase 1? trial where their drug supposedly lowered triglycerides better than Vascepa. It’s an invalid premise on which to say their drug is superior. We all know on this board that the Vascepa effect gets better and better over time and the dose should be administered in accordance with the package instructions not, as I believe Matinas did, in a way to minimize the effect. They are 10 years and $1 billion to fund a long-term large scale outcome study away before they get bragging rights. I’m not buying it